Skip to content

Trial Summary

A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with Breast Cancer



ACTRN/NCT /ethics:


Scientific title:

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001)

Sponsor / Cooperative group:

Aston Sci. Inc.

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2022-02-01
Anticipated End Date2025-12-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Phone08 8359 2565
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting